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The Type Six Secretion System (T6SS) is required for Bordetella bronchiseptica cytotoxic-
ity, cytokine modulation, infection, and persistence. However, one-third of recently
sequenced Bordetella bronchiseptica strains of the predominantly human-associated Com-
plex IV have lost their T6SS through gene deletion or degradation. Since most human B.
bronchiseptica infections occur in immunocompromised patients, we determine here
whether loss of Type Six Secretion is beneficial to B. bronchiseptica during infection of
immunocompromised mice. Infection of mice lacking adaptive immunity (Rag1-/- mice) with
a T6SS-deficient mutant results in a hypervirulent phenotype that is characterized by high
numbers of intracellular bacteria in systemic organs. In contrast, wild-type B. bronchiseptica
kill their eukaryotic cellular hosts via a T6SS-dependent mechanism that prevents survival
in systemic organs. High numbers of intracellular bacteria recovered from immunodeficient
mice but only low numbers from wild-type mice demonstrates that B. bronchiseptica sur-
vival in an intracellular niche is limited by B and T cell responses. Understanding the nature
of intracellular survival during infection, and its effects on the generation and function of the
host immune response, are important to contain and control the spread of Bordetella-
caused disease.
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Introduction
The ability of bacteria to persist inside host cells shields them from antibodies, complement,
and other-extracellular host defenses and thus represents an effective strategy for survival dur-
ing infection. Many bacteria, includingMycobacterium tuberculosis, Salmonella enterica and
Francisella tularensis, employ a variety of different intracellular survival mechanisms to achieve
long-term persistence [1–3]. Until recently, Bordetella species were generally considered exclu-
sively extracellular respiratory pathogens [4], but in vitro studies suggest that the Bordetella
may be able to survive intracellularly [5–12]. However, whether the bacteria utilize this intra-
cellular survival strategy during the infection process remains unclear.
The three Classical Bordetellae, Bordetella bronchiseptica, B. pertussis, and B. parapertussis,
cause a variety of respiratory diseases ranging from asymptomatic infection to fatal pneumonia
[13]. B. pertussis and B. parapertussis are the etiological agents of whooping cough in humans
and are believed to have diverged independently from a B. bronchiseptica-like ancestor [14]. B.
bronchiseptica infects a wide range of mammalian hosts including mice, providing a natural-
host infection model that can allow molecular manipulation of both pathogen and host. B.
bronchiseptica infection induces a significant Th1-type T-lymphocyte cytokine response that is
characterized by high levels of IL-2, IFN-γ, and TNF-α, but low levels of IL-5 and no IL-4
[15,16], and is generally associated with an immune response to intracellular pathogens
[17,18]. Furthermore, the bordetellae were shown to be able to survive intracellularly in vitro in
epithelial cells, dendritic cells (DCs) and macrophages [6–8]. There have been reports of the
recovery of B. pertussis and B. bronchiseptica from bronchiolar lavage of mice, murine nasal
cavity dendritic cells, and alveolar macrophages from HIV-infected patients [19–21], suggest-
ing that intracellular survival is a potential mechanism employed by B. bronchiseptica during
infection. However, the relevance of these observations to natural infection is unclear. Defining
the role of intracellular survival in Bordetella disease has important implications for the devel-
opment of vaccines and therapeutics.
The Type Six Secretion System (T6SS), which is widely distributed amongst Gram-negative
bacteria [22], has been shown to be involved in intracellular survival of several species [23].
Further, up-regulation of most T6SS genes is dependent on contact with or intracellular growth
inside the host cell [24]. In fact, many bacteria persist during infection by utilizing their T6SSs
for intracellular survival and replication, including S. enterica [25], F. tularensis [26], Aeromo-
nas hydrophila [27], and Yersinia pseudotuberculosis [28]. The T6SS in B. bronchiseptica has
been reported to have a function in persistence and immunomodulation during infection [29],
but its contribution to intracellular survival has yet to be characterized.
Despite the important role of the T6SS during B. bronchiseptica infection, a subset of recent
B. bronchiseptica isolates from the predominantly human-associated Complex IV are missing
the T6SS. Since most B. bronchiseptica human infections occur in immunocompromised indi-
viduals [30–35], we aimed to determine whether loss of the T6SS might be beneficial for B.
bronchiseptica during infection of immunocompromised hosts. Here we compare the wild-
type B. bronchiseptica strain RB50 with RB50ΔclpV, an isogenic B. bronchisepticamutant with
an in-frame deletion in the clpV ATPase of the T6SS, during infection of mice lacking adaptive
immunity (B and T cells). We show that loss of T6SS function results in a hypervirulent pheno-
type characterized by early host lethality of immunodeficient mice due to high numbers of pre-
dominantly intracellular bacteria in systemic organs. In contrast, wild-type B. bronchiseptica
kill their cellular hosts via a T6SS-dependent mechanism and are therefore not recovered from
systemic organs. A more careful examination revealed an intracellular stage in the lungs of
both wild-type and immunodeficient mice, demonstrating that B. bronchiseptica can occupy
an intracellular niche during natural host infection. These results reveal the ability of B.
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bronchiseptica to survive intracellularly and demonstrate that both the T6SS and adaptive
immune components contain bacteria within the respiratory tract and limit B. bronchiseptica
intracellular survival during infection.
Materials and Methods
Analysis of clinical strains
The T6SS locus in the genomes of 58 B. bronchiseptica strains isolated from humans (17
strains), a variety of different mammals (31 strains), turkeys (9 strains) and from an unidenti-
fied host (1) were analyzed [36–39]. All genomes were compared against the genome of strain
RB50, and the presence of the T6SS locus (BB0793-BB0818) [29] in the individual genomes as
well as the presence of pseudogenes was assessed visually using the Artemis Comparison Tool
(ACT) [40].
Bacterial Strains and growth
Bordetella bronchiseptica strain RB50 and its isogenic, in-frame deletion mutant RB50ΔclpV
have been previously described [29,41]. RB50 and RB50ΔclpV were grown and maintained on
Bordet-Gengou (BG, Difco) agar supplemented with 10% defibrinated sheep’s blood (Hema
Resources) and 20 ug/ml streptomycin (Sigma). For infections, bacteria were grown overnight
at 37°C to mid-log phase in Stainer Scholte liquid broth (SS).
Mouse Experiments
Four- to six- week old C57Bl/6 and Rag1-/- mice were ordered from Jackson laboratories (Bar
Harbour, ME) and were bred in a pathogen-free facility at the Pennsylvania State Laboratory
(University Park, PA). All experiments were conducted following institutional guidelines, and
all animal experiments were conducted as previously described [29,42,43]. Briefly, the number
of bacterial colony units in liquid SS culture was determined by the optical density measured
by absorbance of light at 600 nm. The bacteria were diluted to 1x107 CFU/mL in phosphate
buffered saline (PBS), and inocula were confirmed by plating dilutions on BG agar and count-
ing resultant colonies after incubation for two days at 37°C. For inoculation, mice were lightly
sedated with 5% isofluorane (IsoFlo, Abbott Laboratories) and were inoculated with 5x105
CFU bacteria by gently pipetting 50 μL of the inoculum onto their external nares. To quantify
bacterial numbers in respiratory tract and systemic organs, mice were euthanized via CO2
inhalation, and the indicated organs were excised. Tissues were homogenized in one mL PBS,
serially diluted and plated on BG agar containing 20 μg/mL streptomycin, and colonies were
counted after incubation at 37°C for two days. Mice with lethal bordetellosis indicated by ruf-
fled fur, hunched stature, and limited responsiveness were euthanized to prevent unnecessary
suffering. For survival curves, Rag1-/- mice were lightly sedated with 5% isofluorane and inocu-
lated with 5x105 CFU RB50 or RB50ΔclpV. Mice were monitored over the course of the experi-
ment and any mice that were hunched over, had labored breathing, or displayed
unresponsiveness or lack of motility were removed from the experiment and euthanized to pre-
vent unnecessary suffering.
Cytokine ELISA
Cytokine analysis was conducted as previously described [44]. Briefly, mice were inoculated
with 5x105 CFU RB50 or RB50ΔclpV and spleens and lungs were collected and homogenized
on day 21 for cytokine analysis. Interleukin 1β (IL-1β), Interleukin 6 (IL-6), Interleukin 10 (IL-
10), Interleukin 17 (IL-17), Tumor Necrosis Factor α (TNF-α), and Interferon Gamma (IFN-
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γ) concentrations were determined via ELISA according to manufacturer’s instructions (R&D
Systems).
Pathology
Twenty-one days following inoculation with RB50 or RB50ΔclpV, mice were euthanized and
the lungs were inflated with 1.5 ml 10% formalin in PBS. Spleens were excised and placed in
10% formalin in PBS. Tissues were processed and stained with hematoxylin and eosin (H&E)
at the Animal Diagnostic Laboratory at the Pennsylvania State University in University Park,
PA. Tissue sections were analyzed and scored on a qualitative scale as previously described [29]
by one of the authors (M.J. Kennett) who is experienced in rodent pathology and was blinded
to the experimental treatments. Descriptive evaluations of lesions were recorded, and lung and
spleen lesions were graded on a scale ranging from 0 to 5: A score of 0 was given for sections
with no lesions and no inflammation; 1 for sections with few lesions (less than 10% tissue
affected) and slight inflammation; 2 indicated mild lesions (11–20% tissue affected); 3 was
given for moderate lesions (21–30% of the lung/spleen tissue affected); 4 had extensive lesions
with marked inflammation (31–50% tissue affected); and a score of 5 was given for samples
exhibiting extensive lesions with high inflammation (>51% lung / spleen tissue affected).
Intracellular Survival Assay
Murine RAW 264.7 macrophages obtained from ATCC (ATCC TIB-71) were grown in Dul-
becco’s modified Eagles medium (DMEM, Difco) supplemented with 10% fetal bovine serum,
1% penicillin-streptomycin, 1% nonessential amino acids, and 1% sodium pyruvate. Cells were
grown to 80% confluency in 5% CO2 in 96-well tissue culture treated plates (Greiner Bio-One)
at 37°C. Cells were primed for two hours with 1000 U/mL recombinant IFNγ in DMEM in 5%
CO2 at 37°C, and then bacterial suspensions of RB50 or RB50ΔclpV were added to wells at a
multiplicity of infection (MOI) of 100. Plates were centrifuged at 5000 RPM for 5 min at room
temperature (RT) and were incubated at 37°C. After 1 hour, 100 μL of 0.1% triton X solution
(Sigma) in PBS was administered to a subset of wells, followed by a 5 minute incubation at RT
and vigorous pipetting to lyse open cells. 10 μL dilutions were serially diluted and plated on BG
to quantify total bacteria (intracellular and extracellular) present after 1 hour. At one hour,
supernatant was removed from remaining wells and replaced with 100 μL of 100 μg/mL genta-
micin solution (Sigma-Aldrich) in DMEM to remaining sample wells. Plates were incubated in
5% CO2 at 37°C, and then at 1, 24, and 48 hours post-gentamicin addition, appropriate wells
were washed 3x with DMEM and treated with 100 μL 0.1% triton X as described above for enu-
meration of intracellular bacteria. At 24 hours, the supernatants were replaced with 10 μg/mL
gentamicin solution in DMEM to prevent uptake of gentamicin into intracellular compartment
of RAW264.7 cells.
Modified Intracellular Survival Assay
Amodified intracellular survival assay conducted on homogenates has been previously
described [19]. Briefly, C57Bl/6 and Rag1-/- mice were inoculated with 5x105 CFU RB50 or
RB50ΔclpV and euthanized on day 21 post-inoculation (p.i.). Nasal cavities, lungs, spleens and
livers were excised and homogenized in one mL PBS. 100 μL of the homogenate was removed
and was serially diluted and plated on BG agar for quantification of total bacteria. Gentamicin
(100 μg/mL) was added to remaining homogenates and samples were incubated for 1 hour at
37°C. After three washes to remove the antibiotic, remaining bacteria were resuspended in
0.1% triton X, serially diluted, and plated on BG supplemented with 20 μg/ml streptomycin for
intracellular bacterial enumeration. As a control to test for gentamicin effectiveness in each
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organ, spleens, livers, lungs, and nasal cavities excised from naïve Rag1-/- mice were homoge-
nized and 107 CFU RB50 or RB50ΔclpV were added to each organ. Gentamicin was shown to
be 99.999% effective at killing extracellular bacteria introduced to lungs, nasal cavity, and
spleen tissues, and 99% effective at killing extracellular bacteria in the liver (data not shown).
Samples were incubated at 37°C for one hour, followed by washes to remove antibiotic, and the
remaining viable bacteria were enumerated via serial dilution and plating on BG agar.
Cytotoxicity Assay
Murine RAW 264.7 macrophages from ATCC were grown in DMEM supplemented with 10%
fetal bovine serum, 1% penicillin-streptomycin, 1% nonessential amino acids, and 1% sodium
pyruvate. Cells were grown to 80% confluency in 5% CO2 in 96-well tissue culture treated
plates (Greiner Bio-One) at 37°C. DMEM was then replaced with RPMI medium lacking phe-
nol red with 5% fetal bovine serum, 1% L-glutamine, 1% nonessential amino acids, and 1%
sodium pyruvate two hours prior to start of the assay. RB50 or RB50ΔclpV were added to plates
at an MOI of 100 and the plates were centrifuged at 5000 RPM for 5 min at RT and were incu-
bated in 5% CO2 at 37°C. One hour later, the supernatant was replaced with 100 μg/mL genta-
micin in RPMI lacking phenol red to kill extracellular bacteria and the plates were incubated
once again in 5% CO2 at 37°C. After one hour or 24 hours, supernatants were collected from
wells and lactate dehydrogenase (LDH) release was measured to quantify levels of cytotoxicity
using a Cytotox96 kit (Promega) according to the manufacturer’s instructions.
IV Injections
RB50 or RB50ΔclpV grown in SS to mid-log phase were re-suspended in PBS and 200 μL of
5x105 CFU/mL were intravenously injected into the tail veins of mice. Mice were dissected 1
and 7 days post-injection and lungs, livers, spleens, and kidneys were homogenized in one mL
PBS, serially diluted and plated on BG agar containing 20 μg/mL streptomycin, and colonies
were counted after incubation at 37°C for two days. Blood was collected via retro-orbital bleed,
spun down at 5000 RPM for 5 min, and serum was then serially diluted, plated, and incubated
at 37°C for two days.
Trypan Blue Exclusion Assay
RAW267.4 macrophage cells were grown in 96 well plates and infected with RB50 or
RB50ΔclpV at an MOI of 100 and incubated at 37°C. Supernatants were replaced with 100 μL
100 μg/mL gentamicin solution after one hour, and one and twenty-four hours post-addition
of gentamicin a subset of RAW264.7 cells were mixed 1:1 with trypan blue dye (Life Technolo-
gies). Total numbers of cells and the number of dead cells were enumerated for each timepoint.
Statistical Analysis
The mean +/- standard error (error bars in figures) was determined for all appropriate data.
Two tailed, unpaired student’s t tests were used to determine statistical significance between
two normally distributed populations. When more than two groups were analyzed, one- and
two-way analysis of variance (ANOVA) tests were used. Survival curves were generated with
the Kaplan-Meier method, and Log-Rank test was used to compute significance. Graphpad
Prism version 6.04 was used to conduct these statistical tests and to generate figures.
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PLOS ONE | DOI:10.1371/journal.pone.0140743 October 20, 2015 5 / 17
Ethics Statement
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was
approved by the Institutional Animal Care and Use Committee at The Pennsylvania State Uni-
versity at University Park, PA (#46284 Bordetella-Host Interactions). All animals were anes-
thetized using isoflourane or euthanized using carbon dioxide inhalation to minimize animal
suffering.
Results
29% of Complex IV B. bronchiseptica isolates have lost their Type Six
Secretion System
The T6SS is a crucial virulence factor for B. bronchiseptica that has been shown to increase
pathology and cytotoxicity, affect cytokine induction, and aid in bacterial persistence during
infection of wild-type mice [29]. However, an analysis of 58 recently sequenced B. bronchisep-
tica isolates revealed that 7 of the total isolates (12%) have lost their entire T6SS locus. In addi-
tion, 3 isolates (5%) contain pseudogenes (referred to in this paper as T6SS-degenerate) in their
T6SS locus, implying that their T6SS may be non-functional. 6 of the 7 T6SS-deficient strains
isolated and one T6SS-degenerate strains are from Complex IV, which is comprised mainly of
human-isolated B. bronchiseptica strains [14]. Thus, 29% of Complex IV strains are T6SS-defi-
cient and 5% are T6SS-degenerated (Fig 1A). In contrast, only 3% of Complex I B. bronchisep-
tica strains analyzed (1/37) are T6SS-deficient and 5% (2/37) are T6SS-degenerated (Fig 1B).
This data suggests that loss of the T6SS may be linked to B. bronchiseptica survival in the
human population, and may contribute to infection of immunocompromised patients.
Deleting the clpV component of T6SS results in hypervirulence in
immunodeficient mice
Since most B. bronchiseptica human infections occur in immunocompromised patients [30–
35,45,46], we hypothesized that T6SS-deficient B. bronchisepticamay be able to infect and per-
sist in immunodeficient mice. To test this, mice lacking T cells, B cells, and antibodies (Rag1-/-
mice) were inoculated with RB50 or RB50ΔclpV, an isogenic mutant lacking the clpV ATPase
gene of the T6SS [29]. While most Rag1-/- mice infected with RB50 survived beyond day 60,
those infected with RB50ΔclpV succumbed to lethal bordetellosis by day 24 p.i. (p<0.05)(Fig
2A). Quantification of RB50 and RB50ΔclpV in respiratory tract organs of Rag1-/- mice on day
21 (prior to death with RB50ΔclpV infection) revealed similar numbers of Bordetella (Fig 2B)
indicating that the hypervirulence of the ΔclpV strain is not caused by increased bacterial load
in the respiratory tract. We therefore hypothesized that the early host death caused by
RB50ΔclpVmay result from systemic bacterial infection. Rag1-/- mice inoculated with either
RB50 or RB50ΔclpV were thus assessed for bacterial numbers in the respiratory tract (nasal
cavity, trachea, and lungs) or systemic organs (liver and spleen) 21 days post-infection. While
similar numbers of RB50 and RB50ΔclpV were recovered from respiratory tract organs, only
RB50ΔclpV was recovered from systemic organs (Fig 2B). These data indicate that a functional
T6SS prevents B. bronchiseptica from colonizing systemic organs of Rag1-/- mice.
In order to determine how rapidly RB50ΔclpV reaches systemic organs, we enumerated bac-
terial numbers on days 3, 7, and 21. RB50ΔclpV was recovered from the liver and spleen of
Rag1-/- mice as early as day 3 p.i., and additionally from the kidneys by day 7. RB50ΔclpV num-
bers then increased in all three organs by day 21 (Fig 2C). In contrast, RB50 was only recovered
from systemic organs on day 3, but was then completely absent or present in only small
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numbers on subsequent days (Fig 2C). A human B. bronchiseptica isolate naturally missing a
T6SS locus [36] (D445) was also recovered systemically from Rag1-/- mice by day 3 p.i. and on
subsequent days (S1 Fig and data not shown). Importantly, both RB50 and RB50ΔclpV were
recovered from systemic organs of immune-competent mice (wild-type C57Bl/6) on day 3 p.i.,
but only RB50ΔclpV was recovered from systemic organs by day 7 p.i., suggesting that the T6SS
limits B. bronchiseptica persistence in systemic organs irrespective of host immune status (S2
Fig). Thus, a functional T6SS limits B. bronchiseptica survival and growth in systemic organs of
immunodeficient and wild-type mice during infection.
RB50ΔclpV systemic infection is not the result of inflammatory response
We hypothesized that immunodeficient mice were dying from an overwhelming inflammatory
response with infection of the mutant. To test this, we performed histological examination of
livers and lungs of infected mice. Rag1-/- mice infected with RB50ΔclpV exhibited higher levels
of inflammation in the liver than those infected with RB50, characterized by primarily perivas-
cular neutrophilic infiltrates with foci of necrosis (p<0.05)(Fig 3A). Despite similar levels of
colonization in the lungs at this timepoint (Fig 1B), infection with RB50ΔclpV resulted in a
trend toward higher inflammatory cell infiltration inflammation and necrosis in the lungs than
infection with RB50 (Fig 3A and data not shown). Also, while RB50 caused no significant
lesions in the liver, RB50ΔclpV caused high hepatic inflammation with primarily perivascular
mixed inflammatory infiltrates by day 21 (Fig 3B).
To determine whether the T6SS modulates local and systemic cytokine production, cytokine
levels were measured in the lungs and spleens of Rag1-/- mice inoculated with RB50 or
RB50ΔclpV. Wild-type RB50 induced lower levels of IL-1β than RB50ΔclpV in the lungs and
spleens of Rag1-/- mice by day 21, indicating that the T6SS suppresses IL-1β production during
Fig 1. Clinical B. bronchiseptica strains that have lost their T6SS locus are aggregated in Complex IV.
Genomes of 58 B. bronchiseptica clinical isolates were compared to prototypical RB50 genome. Presence of
T6SS loci, as well as presence of pseudogenes in T6SS loci, was determined for all clinical isolates. Clinical
strains containing an intact T6SS (blue), strains lacking a T6SS locus (red), and strains containing a
pseudogene in the T6SS locus (pink) were divided based on whether they come from Complex I (A) or
Complex IV (B).
doi:10.1371/journal.pone.0140743.g001
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infection (p<0.05)(Fig 3C). Together, these data suggest that the B. bronchiseptica T6SS modu-
lates innate immunity by lowering pathology, cell recruitment, and IL-1β production both
locally and systemically in Rag1-/- mice.
We hypothesized that spread and subsequent survival of RB50ΔclpV in systemic organs
could be due to the different immune response induced by the mutant, much like S. aureus
lipoprotein mutants generate a variant host response culminating in dissemination and lethal
infection [47]. If this were the case, then co-inoculation with RB50 would provide T6SS-medi-
ated immune modulation that would affect the fate of RB50ΔclpV. Alternatively, if systemic
survival is intrinsic to the bacteria harboring the mutation and not mediated by indirect effects
on the host, then the T6SS-dependent immune response generated by co-infection would not
alter RB50ΔclpV systemic infection. To distinguish between these possibilities, Rag1-/- mice
were inoculated with RB50 alone, RB50ΔclpV alone, or co-inoculated with RB50 and
RB50ΔclpV. Similar numbers of RB50 and RB50ΔclpV were recovered from respiratory tract
organs (lungs and nasal cavities) of Rag1-/- mice by day 21 p.i., regardless of whether they were
inoculated separately or co-inoculated (Fig 4A). However, only RB50ΔclpV was recovered from
systemic organs (p<0.05), and the numbers of RB50ΔclpV recovered from co-inoculated mice
were similar to RB50ΔclpV inoculated alone (Fig 4B). Therefore, a functional T6SS provided by
RB50 in the co-inoculation did not hinder the ability of RB50ΔclpV to reach and remain in
Fig 2. The T6SSmodulates virulence and bacterial dissemination. (A) Groups of Rag1-/- mice (n = 8) were inoculated with 5x105 CFU of RB50 (blue) or
RB50ΔclpV (red) and were monitored for survival. (B) Groups of Rag1-/- mice (n = 4 per group) were inoculated with 5x105 CFU of RB50 (blue) versus
RB50ΔclpV (red) and dissected on day 21 p.i. for bacterial enumeration in respiratory tract and systemic organs. The experiment was performed three times
with similar results and a representative data set is shown. (C) Rag-/- mice were inoculated with 5x105 CFU RB50 (blue) versus RB50ΔclpV (red) and bacteria
were enumerated from the spleen, liver, and kidney on days 3, 7, 21, and 35. With the exception of RB50ΔclpV on day 21 (n = 1), three mice were sacrificed
per group per timepoint. * denotes p value <0.05. Grey dotted line indicates the limit of detection.
doi:10.1371/journal.pone.0140743.g002
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systemic organs by day 21 p.i., and conversely the altered immune response with RB50ΔclpV
infection still did not enable systemic survival of RB50 in the co-infected mice (Fig 4B). Loss of
clpV only affects the bacteria with the mutation, suggesting that the T6SS affects direct interac-
tions between bacteria and immune cells recruited to the site of infection. Additionally, num-
bers of RB50 and RB50ΔclpV were efficiently lowered in systemic organs when injected directly
into the bloodstream (S3 Fig), once again suggesting that the intracellular niche may be utilized
to protect B. bronchiseptica and enable trafficking to systemic organs.
Deletion of clpV increases B. bronchiseptica intracellular survival in vitro
Based on the results above, we hypothesized that B. bronchisepticamanipulates Antigen Pre-
senting Cells (APCs) to house and traffic bacteria to systemic organs during infection, and that
long-term survival in those immune cells is achieved through the loss of the T6SS. To deter-
mine whether loss of the T6SS affects intracellular survival, a gentamicin protection assay was
performed to estimate intracellular survival of RB50 and RB50ΔclpV in RAW264.7 macro-
phages [48]. After a 1 hour treatment with gentamicin, similar numbers of RB50 and
RB50ΔclpV were recovered from RAW264.7 macrophages (Fig 5A) suggesting that
Fig 3. clpV lowers inflammation and pathology in vivo. (A) Groups of four Rag1-/- mice were inoculated with 5x105 CFU of RB50 (blue) or RB50ΔclpV
(red) and a histopathological analysis was conducted on the lung and liver of infected mice on day 21 p.i. for scoring of inflammation. (B) Representative H&E
lung and liver sections from Rag1-/- mice on day 21 p.i. after inoculation with 5x105 CFU of RB50 (blue) or RB50ΔclpV (red) with average pathology scores in
parentheses. (C) Groups of Rag1-/- mice were inoculated with 5x105 CFU RB50 (blue) and RB50ΔclpV (red) and elicited IL-1β levels were determined from
the lung and spleen on day 21 p.i. This experiment was performed twice with similar results and a representative dataset is shown. ND signifies not detected.
* denotes p value <0.05.
doi:10.1371/journal.pone.0140743.g003
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Fig 4. Loss of clpV is required for systemic recovery.Groups of Rag1-/- mice were either infected singly with RB50 (blue circles, n = 3) or RB50ΔclpV (red
circles, n = 4) or co-infected with RB50 and RB50ΔclpV (red squares and blue squares, n = 4), and (A) respiratory tract bacterial numbers or (B) systemic
organ bacterial numbers were enumerated on day 21 post-inoculation. This experiment was performed twice with similar results and a representative dataset
is shown. ND signifies not detected. Grey line indicates the limit of detection.
doi:10.1371/journal.pone.0140743.g004
Fig 5. Deletion of clpV increases intracellular survival in vitro. (A) RAW264.7 macrophages were
infected with RB50 (blue, n = 4) or RB50ΔclpV (red, n = 4) at an MOI of 100 and bacterial invasion and
intracellular survival was determined at 1, 24, and 48 hour after addition of gentamicin. The experiment was
conducted five times with similar results and a representative dataset is shown. (B) The cytotoxicity of
RAW264.7 macrophages infected with RB50 (blue) or RB50ΔclpV (red) at an MOI of 100 was determined 1
hour and 24 hours after gentamicin application. The average percent cytotoxicity of four wells in three
different experiments was measured by (LDH release from a well / LDH release from positive control well) x
100 ±SE is shown. * denotes p value <0.05. Grey line indicates limit of detection.
doi:10.1371/journal.pone.0140743.g005
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phagocytosis and early intracellular survival of B. bronchiseptica is T6SS-independent. How-
ever, after 24 hours numbers of intracellular RB50ΔclpV (~1x105 CFU/mL) were approxi-
mately 1000-fold higher than that of RB50 (~1x102 CFU/mL) (p<0.05) and remained over
1000-fold higher at 48 hours (p<0.05)(Fig 5A). Similarly, infection of RAW264.7 macrophages
with a human isolate naturally lacking its T6SS (D445) yielded similarly high levels of recov-
ered intracellular bacteria by 24 hours (S4 fig). Thus, loss of a functional T6SS increased in
vitro intracellular survival of B. bronchiseptica in RAW264.7 macrophages. A cytotoxicity assay
[29] was performed to analyze whether lower intracellular RB50 recovery by 24 hours corre-
lates with higher cell death. Intracellular RB50 and RB50ΔclpV caused similar levels of cell
death within 1 hour (Fig 5B), but by 24 hours intracellular RB50 caused higher levels of cell
death than RB50ΔclpV (p<0.05)(Fig 5B). A trypan blue exclusion cell viability assay [49] con-
firmed these results (data not shown). Therefore, B. bronchiseptica can survive intracellularly
in RAW264.7 macrophages, but the T6SS inhibits long-term intracellular survival by killing its
eukaryotic host cell. These data suggest that APCs may act as vehicles for the transport of B.
bronchiseptica to systemic organs during in vivo infection and may enable persistence of
RB50ΔclpV in systemic organs of Rag1-/- mice.
The T6SS and adaptive immune components limit in vivo intracellular
survival
To investigate whether the T6SS affects intracellular survival in vivo, we gentamicin treated
homogenized organs recovered from mice inoculated with RB50 or RB50ΔclpV and then enu-
merated surviving (intracellular) bacteria [19]. Less than 1% of RB50 and RB50ΔclpV recovered
from the nasal cavities of both C57Bl/6 and Rag1-/- mice on days 3 and 21 p.i. survived intracel-
lularly (Fig 6A and 6B). However, approximately 4% of RB50 in the lungs of C57Bl/6 mice on
days 3 and 21 p.i. were gentamicin resistant (Fig 6C and 6D), suggesting that a proportion of B.
bronchiseptica survives intracellularly in the lungs during infection and that there may be
organ-specific differences in the proportion of bacteria that are intracellular. A similar propor-
tion of RB50 (5%) was intracellular in lungs of Rag1-/- mice on day 3 p.i., but those numbers
increased to 21% by day 21 p.i. (Fig 6C and 6D). Intracellular B. bronchiseptica was therefore
observed in both wild-type and immunodeficient mice but increased over time only in the lat-
ter, indicating that adaptive immune components control numbers of intracellular B. bronchi-
septica in the lungs.
Fewer total RB50ΔclpV were recovered from the lungs of C57Bl/6 mice by day 3 p.i. than
total RB50, but the proportion of intracellular bacteria recovered at this timepoint were similar
(Fig 6C). By day 21 p.i., RB50ΔclpV numbers in C57/Bl6 lungs were substantially decreased
and no intracellular bacteria were observed (Fig 6D). The T6SS is therefore required for persis-
tence in lungs of immune-competent mice, as was shown previously [29]. In the lungs of
Rag1-/- mice, however, 3% of total RB50ΔclpV were intracellular on day 3 p.i. and those num-
bers increased to 80% by day 21 p.i., which was substantially higher than wild type bacterial
recovery in these animals (Fig 6C and 6D). Hence, loss of the T6SS enables increased recovery
of intracellular B. bronchiseptica from the lungs of immunodeficient mice.
Low numbers of wild-type B. bronchiseptica were recovered from the spleens and livers of
C57Bl/6 mice by day 3 p.i., none of which were intracellular in either organ (Fig 6E and 6G).
Loss of clpV increased the proportion of intracellular bacteria in the spleens and livers of
C57Bl/6 mice 3 days p.i. to 4% and 1%, respectively (Fig 6E and 6G). In Rag1-/- mice
RB50ΔclpV proportions increased to 8% in the spleen and 4% in the liver on day 3 p.i., indicat-
ing that clpV and adaptive immune components both limit intracellular recovery from systemic
organs early during infection (Fig 6E and 6G). While no RB50ΔclpV were recovered from
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Fig 6. Deletion of clpV increases intracellular survival in vivo.Groups (n = 3) of Rag1-/- and C57Bl/6 mice were inoculated with 5x105 CFU RB50 or
RB50ΔclpV and total bacterial numbers (grey) and intracellular RB50 (blue) and RB50ΔclpV (red) numbers were enumerated from the nasal cavity (A, B),
lungs (C, D), spleen (E, F), and liver (G, H) early (day 3) and late (day 21) post-infection. This experiment was conducted twice with similar results and a
representative dataset is shown. Red * denotes p value <0.05 for comparison of intracellular bacterial populations.
doi:10.1371/journal.pone.0140743.g006
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systemic organs of wild-type mice on day 21 p.i., 3% of 104 CFU and 100% of 106 CFU were
recovered intracellularly from the spleen and liver of Rag1-/- mice by day 21, respectively. This
data suggests that that the T6SS prevents accumulation of intracellular B. bronchiseptica in sys-
temic organs and that adaptive immune components are required for clearance of systemic
RB50ΔclpV. Together these results indicate that in immunodeficient mice the T6SS prevents
long-term intracellular survival suggesting that in an immunocompromised host, loss of the
T6SS may aid in B. bronchiseptica persistence.
Discussion
Many species of bacteria, including S. aureus and P. aeruginosa [50,51], utilize virulence factors
to reach the bloodstream and systemic organs during infection. However, in other species bac-
terial factors prevent dissemination to systemic organs [52–54]. Loss of those virulence factors
then causes a hypervirulent phenotype characterized by increased intracellular survival,
enhanced dissemination to blood and systemic organs, and host lethality [52–54]. For example,
loss of covS or lgt in Staphylococcus aureus, sciS in S. enterica, and ccpA in Streptococcus pyo-
genes all lead to hypervirulence and increased host lethality [47,52–54]. Although the B.
bronchiseptica T6SS is required for persistence during infection of wild-type mice [29], we
show that loss of this secretion system contributes to enhanced intracellular survival leading to
early host death of immunodeficient mice. A large proportion of recently sequenced B. bronchi-
septica strains are T6SS-negative (Fig 1), suggesting that while this secretion system plays an
important role during infection [29], loss of the T6SS may also benefit B. bronchiseptica by
enhancing intracellular survival. Here we showed that T6SS-deficiency is detrimental for B.
bronchiseptica survival in the lungs of wild-type C57Bl/6 mice (Fig 6A and 6B). However, dis-
ruption of T6SS function is also detrimental for B. bronchiseptica in adaptive immunodeficient
mice; while high numbers of RB50ΔclpV survived intracellularly at the site of infection, the
spread of mutant to systemic organs via long-term survival in APCs contributed to host death,
representing a “dead-end” for B. bronchiseptica (Figs 6 and 2). A similar phenotype for the
T6SS has also been reported forHelicobacter hepaticus, where this secretion system plays a pro-
tective role by decreasing intracellular bacterial numbers within intestinal epithelial cells and
by modulating host inflammation [55]. Since B. bronchiseptica kills its eukaryotic cellular host
via a T6SS-mediated mechanism, a functional T6SS appears to be required for containment of
the bacteria to the respiratory tract in immunocompromised mice and may potentially increase
likelihood of transmission and ultimate success of this pathogen. In this work, we have not
determined how the wild-type B. bronchiseptica are cleared from systemic organs of immuno-
compromised mice, and it will be interesting to elucidate the specific mechanism of clearance
in future. Future work will determine whether loss of this secretion system correlates with
intracellular recovery from clinical isolates of immunodeficient patients, and whether T6SS-
deficient B. bronchiseptica strains are able to persist in the population because of their
enhanced survival in an immunocompromised niche.
An adaptive immune response is required to contain B. bronchiseptica within the respira-
tory tract and to limit intracellular B. bronchiseptica numbers. Either B cells or T cells are suffi-
cient to limit systemic T6SS-negative bacteria, though both are required for efficient clearance
from the lungs (Bendor and Harvill, unpublished). However, a proportion of T6SS-sufficient B.
bronchiseptica were recovered intracellularly from the lungs of wild-type mice during infection
(Fig 6C and 6D). Intracellular localization shields these wild-type B. bronchiseptica from com-
plement, antibodies, and other antimicrobials released during inflammation, potentially allow-
ing them to evade these responses and emerge after resolution of the local inflammatory
response. Future work will determine mechanisms of intracellular survival for these T6SS-
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sufficient B. bronchiseptica, including whether the wild-type bacteria persist within or repeat-
edly infect cells and whether they regulate expression of virulence factors and modulate host
cell behavior in order to maintain their intracellular localization.
Intracellular survival of the T6SS-deficient bacteria appears to be niche specific as more intra-
cellular bacteria were recovered in the lungs and livers than in the nasal cavities and spleens,
respectively, during infection (Fig 6A–6D). This differential intracellular survival could be attrib-
uted to altered immune surveillance and response in different organs. Increased intracellular sur-
vival in the liver as compared to the spleen has also been observed with mycobacteria, where a
varying immune response accounted for these differences [56]. In addition, dissimilar architecture
or cellular populations of the two organs may have contributed to differences in intracellular bac-
terial recovery. While we used the spleen as a representative systemic organ for immune response
analysis to RB50 or RB50ΔclpV infection in Rag1-/- mice (Fig 3C), it will be interesting to deter-
mine whether a different immune response in the liver contributes to the higher proportion of
surviving intracellular B. bronchiseptica during infection (Fig 6F and 6H). Also, further work iden-
tifying the cell types housing Bordetella in the respiratory tract and systemic organs may shed
light on the niche-specific differences in intracellular survival that were reported in this study.
All three classical bordetellae (B. bronchiseptica, B. pertussis, and B. parapertussis) have been
shown to be able to survive intracellularly [5,8,11,12,57]. Of the three, B. bronchiseptica is the
only species predicted to have a functional T6SS [36] while the T6SS is absent from B. pertussis
and degenerated in B. parapertussis [36,39]. Additionally, O antigen has been reported to medi-
ate B. parapertussis survival in neutrophils [12] but B. pertussis lacks the O antigen locus [39],
indicating that an alternative factor is likely required for intracellular survival of B. pertussis.
The T3SS appears to function similarly to the T6SS by limiting intracellular survival and sys-
temic recovery of B. bronchiseptica [58] (Bendor and Harvill, unpublished), but is probably not
functional in B. parapertussis because of pseudogenes present in the locus [39]. Lastly, higher
levels of B. bronchiseptica Bvg- mutants have been recovered intracellularly in vitro than wild-
type [6], but in contrast B. pertussis appears to require Bvg function for invasion and intracellu-
lar survival in macrophages in vitro [59]. Thus, there seem to be different mechanisms for
intracellular survival in these three closely related species, and we have identified a system in
which we can dissect their varying intracellular survival strategies. This system will be useful to
investigate when and how Bordetella species utilize an intracellular niche during infection,
which will provide essential information for the design of improved vaccines and therapeutics.
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S1 Fig. B. bronchiseptica isolate naturally missing the Type Six Secretion System is able to
colonize systemic organs of Rag1-/- mice. RB50 (blue), RB50ΔclpV (red) and D445 (green)
recovery from livers of Rag1-/- mice on day 7 p.i. Grey line indicates limit of detection.
(TIFF)
S2 Fig. Deletion of clpV increases systemic persistence in both immunodeficient and wild-
type mice. RB50 (blue) and RB50ΔclpV (red) recovery from livers and spleens of Rag1-/- and
wild-type C57Bl/6 mice on days 3 (A) and 7 (B) p.i.  denotes p value<0.05.
(TIFF)
S3 Fig. RB50 and RB50ΔclpV are both efficiently cleared when intravenously injected into
mice. RB50 (blue) and RB50ΔclpV (red) recovery from lungs, livers, spleens, and kidneys of
Rag1-/- mice that had been intravenously injected and dissected on days 1 (A) and 7 (B) p.i.
ND—Not Detected. The grey line indicates limit of detection.
(TIFF)
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S4 Fig. A B. bronchiseptica isolate naturally missing the Type Six Secretion System survives
intracellularly in vitro. Invasion and intracellular survival of RB50ΔclpV (red) and a B. bronch-
iseptica isolate naturally missing the T6SS (D445, green) in RAW264.7 macrophages at an
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